SCHEMBL4797487

SCHEMBL4797487

Cc1ncc(Oc2ccc([NH])cc2Cl)cn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.46
MPO P05164 1/20 0.40
TPO P07202 1/20 0.40
EPX P11678 1/20 0.40
LPO P22079 1/20 0.40
S1PR4 O95977 2/20 0.33
LMNA P02545 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
ALDH1A1 P00352 1/20 0.31
ACACB O00763 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
AR P10275 1/20 0.31
OXTR P30559 1/20 0.31
F2 P00734 1/20 0.31
F10 P00742 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4799461 0.84 MPO (0.44) GRM4MPOTPOEPXLPO
SCHEMBL4798387 0.83 CYP1A2 (0.36) GRM4CYP1A2CYP3A4CYP2C19
SCHEMBL4799203 0.81 AR (0.38) GRM4ALDH1A1AR
SCHEMBL4797494 0.81 GRM4 (0.51) GRM4MPOTPOEPXLPO
SCHEMBL4794746 0.78 GRM2 (0.42) GRM4S1PR4ALDH1A1
SCHEMBL4795738 0.77 MPO (0.31) MPOTPOEPXLPOS1PR4
SCHEMBL4798748 0.75 OXTR (0.39) GRM4S1PR4LMNAALDH1A1ACACB
SCHEMBL4797723 0.75 F2 (0.37) MPOTPOEPXLPOLMNA
SCHEMBL4800458 0.74 LMNA (0.38) S1PR4LMNAPTGS1PTGS2ALDH1A1
SCHEMBL4800351 0.74 MPO (0.36) MPOTPOEPXLPOLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332493-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth OSI PHARMACEUTICALS (US) 2008-02-19 US claimed
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US claimed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US claimed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP claimed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US disclosed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP disclosed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 GRM4 3324/4885MPO 4395/4885TPO 4817/4885
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 GRM4 4041/4885MPO 4330/4885TPO 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.